TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24139256
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine hydrochloride with 12.5 μg/mL epinephrine
Study: 24139256
Drug: physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: physiological saline solution
Study: 12795037
Drug: Methotrexate treatment
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate treatment for progressive MS
Study: 1626732
Drug: Pentoxifylline, oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline, oral administration at a dose of 1,200 mg daily during healing and 400 mg daily during ulcer-free intervals
Study: 1626732
Drug: Deferoxamine, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferoxamine, intravenous dose of 20 mg/kg
Study: 3890639
Drug: Atropine (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.05 mg/kg)
Study: 31780002
Drug: Foot reflexology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot reflexology (15 min on each foot, total 30 min, twice a week for six weeks)
Study: 27097163
Drug: Antimicrobial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial treatment for 8 weeks
Study: 16860046
Drug: 4-day hormone-free
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-day hormone-free interval (HFI)
Study: 16860046
Drug: 7-day hormone-free
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-day hormone-free interval (HFI)
Study: 12826045
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m2 as a 3-h infusion followed by carboplatin at AUC 6 every 3 weeks for three courses
Study: 1321056
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (1.6 mg.day‐1 for 7 days)
Study: 1321056
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (30 mg.day‐1 for 3 days)
Study: 1321056
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose oral dexamethasone (8 mg.day‐1 for 2 days)
Study: 6148382
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg LI 32-468
Study: 6148382
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg LI 32-468
Study: 6148382
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg LI 32-468
Study: 31682194
Drug: Mentalization-Based Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization-Based Treatment in a day hospital setting (MBT-DH)
Study: 31682194
Drug: Specialist Treatment
Normalized name: Centrum Specialist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialist Treatment as Usual (S-TAU)
Study: 30448598
Drug: Besifovir dipivoxil
Normalized name: Besifovir dipivoxil
DrugBank: Besifovir dipivoxil (DB05020)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Besifovir dipivoxil maleate (BSV) 150 mg
Study: 23839751
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein isolate (20 g daily)
Study: 29440154
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive surgical treatment
Study: 18645042
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment by functional bracing
Study: 11194948
Drug: 3D-conformal-radiation therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D-conformal-radiation therapy (3D-CRT)
Study: 11194948
Drug: 3D-conformal-radiation therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D-conformal-radiation therapy (3D-CRT) with escalated dose (+10 or 15%)
Study: 8690970
Drug: THELEP‐recommended regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: THELEP‐recommended regimen (600 mg rifampin, 600 mg clofazimine supervised on two consecutive days monthly, 225 mg diacetyl diaminodiphenylsulfone bimonthly, 100 mg dapsone daily unsupervised)
Study: 8690970
Drug: Conventional MDT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional MDT (600 mg rifampin, 300 mg clofazimine supervised once a month, 100 mg dapsone daily unsupervised, 50 mg clofazimine daily unsupervised)
Study: 24380385
Drug: Weight reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight reduction advice in the form of an Energy Prescription (EP)
Study: 20666814
Drug: Interoperative irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interoperative irrigation with sterile saline solution
Study: 18239197
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg trihexyphenidyl
Study: 16603147
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Fe daily
Study: 16603147
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Fe twice weekly
Study: 12453547
Drug: Nebivolol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (2.5 and 5 mg)
Study: 7717236
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 0.6 mg/kg 20-30 min before cystourethrography
Study: 2038109
Drug: ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen 800 mg
Study: 31945548
Drug: aPDT as
Approvals — FDA: no, EMA: no, PMDA: no
Description: aPDT as an adjunct to ultrasonic scaling (US)
Study: 31945548
Drug: PBM as
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBM as an adjunct to ultrasonic scaling (US)
Study: 23802640
Drug: Ascorbic acid,
Normalized name: ASCORBIC ACID, (-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascorbic acid, 500 mg every eight hours, administered three times per day for 48 hours prior to bleaching sessions.
Study: 23802640
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered three times per day for 48 hours prior to bleaching sessions.
Study: 21416238
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + subgingival minocycline administration
Study: 19258143
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of 1% lidocaine
Study: 17445928
Drug: Radiotherapy (RT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy (RT) - 50 Gy/25 fx/5 weeks followed by 12 Gy/2 fx of high-dose-rate intra-lumenal brachytherapy (initially), later modified to 66 Gy/33 fx/6.5 weeks.
Study: 17445928
Drug: Cisplatin chemo-radiotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin chemo-radiotherapy (CRT) - identical radiotherapy with concurrent weekly cisplatin at 35 mg/m2 for 6-7 cycles.
Study: 10440800
Drug: Combined hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hepatitis A and B vaccine (two-dose schedule)
Study: 10440800
Drug: Monovalent vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent vaccines (two-dose schedule)
Study: 2117799
Drug: OKT3 as
Normalized name: Humanized OKT3
DrugBank: Teplizumab (DB06606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKT3 as a prophylactic agent
Study: 371743
Drug: Clindamycin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (600 mg i.m.)
Study: 371743
Drug: Cefazolin (1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1.1 g i.m.)
Study: 30778649
Drug: Betrixaban (full-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betrixaban (full-dose stratum)
Study: 30778649
Drug: Enoxaparin (full-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (full-dose stratum)
Study: 17910330
Drug: Levocetirizine, 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine, 0.125 mg/kg, twice daily for 18 months
Study: 8877910
Drug: 13C-urea breath
Normalized name: 13C-urea
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 13C-urea breath test (13C-UBT) with 38 mg 13C-urea
Study: 3741533
Drug: Intravenous theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous theophylline (0.48 g of theophylline-ethylenediamine, TE)
Study: 3741533
Drug: Retention enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retention enema (400 mg theophylline, 600 mg diprophylline, 600 mg proxyphylline, TDP)
Study: 29239764
Drug: Dipeptidyl peptidase
Normalized name: Dipeptidyl peptidase I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipeptidyl peptidase 4 inhibitors (DPP‐4i)
Study: 1909748
Drug: Transdermal nitrate
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitrate therapy
Study: 1909748
Drug: Oral nitrate
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nitrate therapy
Study: 6397454
Drug: Indomethacin together
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin together with low dose dopamine infusion
Study: 24524214
Drug: 9-week online
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9-week online insomnia treatment programme, Sleep Healthy Using The internet (SHUTi)
Study: 20231896
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium stibogluconate (SSG) 20mg/kg/day for ten doses
Study: 20231896
Drug: Localized ThermoMed
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Localized ThermoMed (TM) device heat treatment (applied at 50 degrees C for 30 seconds) in one session
Study: 17398320
Drug: 5 IU/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 IU/ml low-molecular-weight heparin (LMWH) and 200 mug/ml 5-Fluorouracil (5FU) added to the perioperative infusion fluid
Study: 12188401
Drug: Simvastatin (Zocor),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (Zocor), dosage 10 mg
Study: 12188401
Drug: Generic simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic simvastatin (Unison), dosage 10 mg
Study: 8887188
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (OC) therapy after GnRH-a administration
Study: 8887188
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (GnRH-a plus OC 'addback') for six months
Study: 30302335
Drug: Once daily,
Normalized name: Austedo XR Once Daily, 4 Week Titration Pack, 6 MG / 12 MG / 24 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 µg
Study: 30302335
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily budesonide/formoterol (BUD/FOR) 400/12 μg
Study: 21159473
Drug: Diphenhydramine 20
Normalized name: dextromethorphan/phenylephrine/acetaminophen/diphenhydramine 20 mg-10 mg-575 mg-37.5 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 20 mg
Study: 20137360
Drug: Morphine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.15 mg/kg; maximum 20 mg)
Study: 16512103
Drug: Yogurt containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt containing Bifidobacterium DN-173 010 (200 g once daily for 2 weeks)
Study: 16512103
Drug: Control yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control yogurt without viable bacteria (200 g once daily for 2 weeks)
Study: 9951429
Drug: R-568 (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-568 (calcium receptor agonist)
Study: 9951429
Drug: R-568 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-568 (80 to 160 mg doses)
Study: 7844610
Drug: Diethyldithiocarbamate (DDTC)
Normalized name: diethyldithiocarbamate
DrugBank: Ditiocarb (DB02520)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethyldithiocarbamate (DDTC) 1.6 g/m2 over 4 hours, administered intravenously every 4 weeks for six cycles
Study: 7844610
Drug: Placebo (PB),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PB), administered intravenously every 4 weeks for six cycles
Study: 2189954
Drug: MVAC chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVAC chemotherapy
Study: 2189954
Drug: CISCA chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CISCA chemotherapy
Study: 446321
Drug: Additional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional treatment with piracetam (Normabrain, Nootrop, 9 g/d intravenously)
Study: 26031193
Drug: 5-HTP (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HTP (100 mg orally)
Study: 23609398
Drug: haloperidol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol (2.5 mg) + midazolam (7.5 mg)
Study: 23609398
Drug: haloperidol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol (2.5 mg) + promethazine (25 mg)
Study: 23609398
Drug: ziprasidone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ziprasidone (10 mg)
Study: 21893650
Drug: Cycled therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycled therapy (tobramycin inhalation solution 300 mg twice a day for 28 days + oral ciprofloxacin 15-20 mg/kg twice a day for 14 days every quarter)
Study: 21893650
Drug: Culture-based therapy
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culture-based therapy (same treatments only during quarters with positive P aeruginosa cultures)
Study: 21893650
Drug: Ciprofloxacin (15-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (15-20 mg/kg twice a day for 14 days every quarter)
Study: 21893650
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral placebo for 14 days every quarter)
Study: 21893650
Drug: Cycled therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycled therapy
Study: 21893650
Drug: Culture-based therapy
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culture-based therapy
Study: 15363569
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg clomipramine
Study: 11731062
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BTXA) injection
Study: 9230003
Drug: Intravenous amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amphotericin B lipid complex at 5 mg/kg total dose (1 mg/kg per day for 5 days)
Study: 9230003
Drug: Intravenous amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amphotericin B lipid complex at 10 mg/kg total dose (2 mg/kg per day for 5 days)
Study: 9230003
Drug: Intravenous amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amphotericin B lipid complex at 15 mg/kg total dose (3 mg/kg per day for 5 days)
Study: 2902812
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg kg‐1 cimetidine (groups 3 and 5)
Study: 2902812
Drug: 0.2‐0.3 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2‐0.3 mg kg‐1 etomidate (groups 2 and 3)
Study: 2902812
Drug: 2‐3 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐3 mg kg‐1 thiopentone (groups 1, 4, 5 and 6)
Study: 2902812
Drug: 0.08 mg
Normalized name: mestranol 0.08 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.08 mg kg‐1 vecuronium
Study: 2902812
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg kg‐1 ranitidine (group 6)
Study: 2902812
Drug: 0.002 mg
Normalized name: niacin 0.002 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.002 mg kg‐1 fentanyl and 0.01 mg kg‐1 lormetazepam
Study: 25315258
Drug: Axitinib 5
Normalized name: axitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib 5 mg twice daily
Study: 21884529
Drug: Azithromycin (AZM)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (AZM) 500 mg for 3 days during the first week, followed by 500 mg per week for the next 11 weeks
Study: 17898353
Drug: Amisulpride (dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (dopamine D(2)/D(3) antagonist)
Study: 15485015
Drug: Cortivazol (Altim)
Normalized name: cortivazol
DrugBank: Cortivazol (DB13003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortivazol (Altim) 3.75 mg
Study: 11152924
Drug: Vaginal preparation
Normalized name: Trichomonas vaginalis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal preparation with povidone iodine
Study: 11152924
Drug: No preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preparation (control)
Study: 9766255
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rh-GH) 0.5-1 IU/day s.c., bedtime (n=8)
Study: 3041874
Drug: Plasmapheresis (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmapheresis (10 ml plasma/kgbw) using a Haemonetics separator (PCS) after premedication before anaesthesia.
Study: 26350489
Drug: Autologous adipose-derived
Normalized name: Autologous adipose-derived stromal vascular fraction cells
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous adipose-derived stromal vascular fraction (ADSVF) injection
Study: 24286192
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral MPA (10 mg daily for 6 months)
Study: 24286192
Drug: Cyclic oral
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic oral MPA (10 mg for 10 days per cycle for 6 months)
Study: 24330904
Drug: EPA/DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA/DHA supplementation as monotherapy (n = 125)
Study: 24330904
Drug: EPA/DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA/DHA supplementation as adjunctive to conventional antidepressants (n = 33)
Study: 20957321
Drug: Dydrogesterone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dydrogesterone (5 mg)
Study: 20957321
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus Vitamin D (500 mg calcium + 200 mg vitamin D)
Study: 18375891
Drug: darbepoetin/iron (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: darbepoetin/iron (sodium ferric gluconate 125 mg IV weekly for the first 6 weeks)
Study: 16753767
Drug: L-arginine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (20 g/500 mL) administered via i.v. infusion for 4 consecutive days
Study: 16753767
Drug: L-arginine (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (in subgroup not receiving antihypertensive drugs)
Study: 16753767
Drug: Placebo (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (in subgroup not receiving antihypertensive drugs)
Study: 9554154
Drug: Western blot
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western blot method for detecting antibodies against rotavirus proteins
Study: 7699621
Drug: Low-dose methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methotrexate (MTX) therapy
Study: 29074041
Drug: Sham operation
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham operation with water for injection
Study: 27493136
Drug: Empagliflozin 12.5
Normalized name: empagliflozin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 12.5 mg b.i.d. + Metformin 1,000 mg b.i.d.
Study: 27493136
Drug: Empagliflozin 12.5
Normalized name: empagliflozin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 12.5 mg b.i.d. + Metformin 500 mg b.i.d.
Study: 27493136
Drug: Empagliflozin 5
Normalized name: empagliflozin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 5 mg b.i.d. + Metformin 1,000 mg b.i.d.
Study: 27493136
Drug: Empagliflozin 5
Normalized name: empagliflozin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 5 mg b.i.d. + Metformin 500 mg b.i.d.
Study: 27493136
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg q.d.
Study: 27493136
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg q.d.
Study: 27493136
Drug: Metformin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1,000 mg b.i.d.
Study: 22050786
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg b.i.d.
Study: 23761968
Drug: RSDM+ (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSDM+ (monthly risedronate 150 mg and cholecalciferol 30,000 IU combined in a single pill, n = 74)
Study: 23761968
Drug: RSDM (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSDM (monthly risedronate 150 mg alone, n = 76)
Study: 18544983
Drug: Adjuvant radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radiotherapy (total doses of 60 Gy with single doses of 2 Gy)
Study: 11071188
Drug: Sodium cromoglicate
Normalized name: Sodium cromoglicate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglicate by inhalation
Study: 28646587
Drug: Mini-catheter for
Normalized name: oxymetazoline hydrochloride Nasal Solution [Iliadin Mini]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-catheter for local anesthetic injection (chirochaine 0.125% w/v; 20 mL bolus before consciousness, followed by three consecutive injections of 20 mL each at 8, 16, and 24 hours post-surgery)